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Cancer development not only depends on genetic alterations but 
also on epigenetic changes (1–3). These changes modify gene ex-
pression through DNA methylation, histone modifications, chro-
matin remodeling, and/or the expression of noncoding RNA (4–6). 
The reversibility of epigenetic gene silencing provides new oppor-
tunities for treatment based on the use of DNA methyltransferase 
inhibitors, like zebularine (7), or histone deacetylase inhibitors, 
such as suberoylanilide hydroxamic acid (8,9).
Until  very  recently,  epigenetic  gene  silencing  in  cancer  was 
thought to be restricted to focal events that silenced isolated genes 
(10). However, recent findings have indicated that epigenetic silencing 
can extend to a whole chromosomal region and has been reported to 
involve  DNA  methylation  and/or  histone  modification  in  various 
cancers (bladder, breast, colorectal, and prostate cancer) (11–14).
The goal of this study was to take a global view, at the genome 
scale,  of  regional  epigenetic  silencing  in  malignant  vs  normal 
urothelium and to assess its clinical relevance to tumor progres-
sion.  We  previously  developed  a  bioinformatics  method  that 
combines transcriptome and comparative genome hybridization 
array data from the same set of tumors to obtain an overview of 
the  regional  transcriptional  deregulation  that  occurs  indepen-
dently of DNA copy number changes (11). The application of this 
method to a series of 57 bladder tumors led to the identification 
of 28 regions that harbored groups of neighboring genes with 
correlated  expression  independent  of  copy  number  changes. 
Epigenetic silencing affecting multiple neighboring genes was one 
possible mechanism that could account for this regional corre-
lated expression (11).
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  Background  Epigenetic silencing can extend to whole chromosomal regions in cancer. There have been few genome-wide 
studies exploring its involvement in tumorigenesis.
  Methods  We searched for chromosomal regions affected by epigenetic silencing in cancer by using Affymetrix microar-
rays and real-time quantitative polymerase chain reaction to analyze RNA from 57 bladder tumors compared 
with normal urothelium. Epigenetic silencing was verified by gene re-expression following treatment of bladder 
cell lines with 5-aza-deoxycytidine, a DNA demethylating agent, and trichostatin A, a histone deacetylase inhib-
itor. DNA methylation was studied by bisulfite sequencing and histone methylation and acetylation by chroma-
tin immunoprecipitation. Clustering was used to distinguish tumors with multiple regional epigenetic silencing 
(MRES) from those without and to analyze the association of this phenotype with histopathologic and molecular 
types of bladder cancer. The results were confirmed with a second panel of 40 tumor samples and extended in 
vitro with seven bladder cancer cell lines. All statistical tests were two-sided.
  Results  We identified seven chromosomal regions of contiguous genes that were silenced by an epigenetic mechanism. 
Epigenetic  silencing  was  not  associated  with  DNA  methylation  but  was  associated  with  histone  H3K9  and 
H3K27 methylation and histone H3K9 hypoacetylation. All seven regions were concordantly silenced in a sub-
group of 26 tumors, defining an  MRES phenotype. MRES tumors exhibited a carcinoma in situ–associated gene 
expression signature (25 of 26 MRES tumors vs 0 of 31 non-MRES tumors, P < 10214), rarely carried FGFR3 
mutations (one of 26 vs 22 of 31 non-MRES tumors, P < 1026), and contained 25 of 33 (76%) of the muscle-
invasive tumors. Cell lines derived from aggressive bladder tumors presented epigenetic silencing of the same 
regions.
  Conclusions  We have identified an  MRES phenotype characterized by the concomitant epigenetic silencing of several chro-
mosomal regions, which, in bladder cancer, is specifically associated with the carcinoma in situ gene expres-
sion signature.
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In this current report, we have determined which of the 28 
regions are epigenetically silenced by 1) identifying regions that 
harbor stretches of adjacent genes with decreased expression in 
tumors with respect to normal urothelium, and 2) searching for an 
epigenetic mechanism, such as DNA methylation and/or histone 
modification, that might be responsible for this decreased expres-
sion.  We  then  investigated  whether  the  epigenetically  silenced 
regions were randomly distributed among tumors or whether they 
occurred together in a particular subset of tumors, defining a mul-
tiple regional epigenetic silencing (MRES) phenotype. Finally, we 
analyzed whether this silencing mechanism was related to one of 
the two pathways of bladder tumor progression: the carcinoma in 
situ (CIS) pathway or the low-grade Ta tumor pathway.
Methods
Patients and Tissue Samples
The  first  set  of  57  bladder  carcinomas  were  obtained  from  53 
patients who were included between 1988 and 2001 in the pro-
spective  database  established  in  1988  at  the  Department  of 
Urology of Henri Mondor Hospital (Créteil, France). These can-
cers were selected randomly from a consecutive set, to cover the 
different stages of bladder cancer as follows: 16 Ta, eight T1, seven 
T2, 13 T3, and 13 T4 tumors. An additional criterion for inclusion 
was the availability of both tumor RNA and DNA. Three patients 
had multiple bladder tumors, two with one additional tumor and 
one with two additional tumors. Five normal urothelial samples 
were  also  used  for  transcriptome  analysis.  They  were  obtained 
from fresh urothelial cells scraped from the normal bladder wall 
and dissected from the lamina propria during organ procurement 
from cadaveric donors for transplantation, as previously described 
(15).  A  second  independent  set  of  40  bladder  carcinomas  was 
obtained from tumor tissue banks at Henri Mondor Hospital (n = 
18), Institut Gustave Roussy (n = 9) (Villejuif, France), and Foch 
Hospital (n = 13) (Suresnes, France). These tumors, sampled from 
40 patients treated between 1993 and 2006, were selected so as to 
obtain a distribution of tumor stages similar to that for the first set 
of 57 cancers: 10 Ta, six T1, six T2, seven T3, and 11 T4. The 
characteristics of the patients and the tumors in the two sets are 
summarized in Table 1. All patients provided written informed 
consent and the study was approved by the ethics committees of 
the different hospitals.
RNA and DNA Extraction from Tissues
Immediately after surgery, the samples were frozen in liquid nitro-
gen and stored at 280°C until nucleic acid extraction. RNA and 
DNA were extracted from the surgical samples by cesium chloride 
density centrifugation (18). Briefly, the frozen samples were ho-
mogenized in 4 M guanidium thiocyanate with an Ultraturrax T25 
homogenizer  (Janke  &  Kunkel,  IKA-Labortechnik,  Staufen, 
Germany),  overlaid  on  a  5.7  M  cesium  chloride  cushion  and 
centrifuged.  RNA  was  found  in  the  pellet,  whereas  DNA  was 
found on the top of the cesium chloride cushion. RNA and DNA 
were further purified by phenol–chloroform extraction and eth-
anol precipitation. The concentration, integrity and purity of each 
RNA sample were determined with the RNA 6000 LabChip Kit 
(Agilent Technologies, Massy, France) and an Agilent 2100 bio-
analyzer. DNA purity was also assessed from the ratio of absor-
bances at 260 and 280 nm. DNA concentration was determined 
with a Hoechst dye-based fluorescence assay (19).
Affymetrix Array Analyses
We have previously reported the Affymetrix gene expression pro-
file of the 57 urothelial bladder carcinomas (53 tumors from 53 
patients plus four additional tumors from these patients) (11). For 
all Affymetrix array expression analyses, Affymetrix MAS5 signal 
values were log2-transformed and normalized by removing chip-
specific and probe set–specific effects (the mean signal for all probe 
sets across one chip and the mean signal for one probe set across 
all chips, respectively).
Clustering Analyses
The Cluster 3.0 program (20) was used for hierarchical clustering. 
Results were displayed with the TreeView program (20). Cluster 
analyses were used to identify, from Affymetrix expression data, 
regions of correlated increased or decreased expression indepen-
dent of copy number changes, in subsets of tumor samples. For the 
identification of regions that had decreased (or increased) expres-
sion independent of copy number losses (or gains) in a subset of 
CONTEXT AND CAVEATS
Prior knowledge
Although the epigenetic silencing of isolated genes has often been 
reported  and  studied  in  detail  in  cancer,  there  have  been  few 
studies on the silencing of entire chromosomal regions and its as-
sociation with tumor progression.
Study design
Microarrays, reverse transcription–polymerase chain reaction, in-
hibitors of DNA modification, and chromatin immunoprecipitation 
were  used  to  evaluate  epigenetic  silencing  in  28  chromosomal 
regions among two sets of bladder tumors (N = 57 + 40) and seven 
bladder cancer cell lines. Clustering software was used to identify 
tumors with “multiple regional epigenetic silencing” (MRES) and 
the association of this phenotype with molecular gene signatures 
and histological types of bladder cancer.
Contribution
Seven  stretches  of  contiguous  genes  were  found  to  be  concur-
rently silenced in 26 of 57 tumors by a mechanism involving his-
tone methylation and hypoacetylation. Among bladder tumors and 
cell lines, the MRES phenotype was tightly associated with what 
was reported to be a carcinoma in situ (CIS) gene expression sig-
nature, the absence of FGFR3 mutations, and a more aggressive 
phenotype.
Implications
A new epigenetic phenomenon the  MRES phenotype, is described 
in cancer. It appears to often be associated with carcinoma in situ 
among bladder cancers.
Limitations
More  studies  will  be  necessary  to  verify  the  reported  CIS  gene 
signature and to evaluate the relationship of the MRES phenotype 
with carcinoma in situ progression and with patient prognosis.
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tumors, the clustering approach was applied to those tumors with-
out copy number losses (or gains). Cluster analyses using Affymetrix 
or  TaqMan  low-density  array  data  were  also  used  to  identify 
tumors with the multiple region epigenetic silencing (MRES) phe-
notype  and  to  identify  tumors  with  the  CIS  signature  using 
Affymetrix or TaqMan low-density array data.
Cell Culture
The human bladder cancer cell line CL1207 was derived from 
tumor T1207 of the first tumor set, as previously described (21). 
The human bladder cancer cell lines TCCSUP, HT1376, RT112, 
T24, MGHU3, and CL1207 were cultured in Dulbecco’s modi-
fied Eagle medium F-12 Glutamax medium (Invitrogen, Cergy 
Pontoise,  France)  supplemented  with  10%  fetal  bovine  serum 
(Lonza Verviers, Verviers, Belgium); the human bladder cancer 
cell line JMSU1 was cultured in Roswell Park Memorial Institute 
(RPMI) Glutamax medium (Invitrogen) supplemented with 10% 
fetal  bovine  serum.  HT1376,  RT112,  T24,  and  JMSU1  were 
obtained  from  DKFZ  (Heidelberg,  Germany).  TCCSUP  was 
obtained  from  the  laboratory  of  D.  Chopin  (Hôpital  Henri 
Mondor, Créteil, France) and MGHU3 from the laboratory of   
Y. Fradet (University of Laval, Québec, Canada). To verify the 
identity of the various cell lines used, we analyzed the genomic 
alterations with comparative genomic hybridization (CGH) arrays 
(22)  and  FGFR3,  TP53,  HRAS,  and  KRAS  mutations  with  the 
SNaPshot technique (for FGFR3, see below) or classical sequencing 
for the other genes. CGH array profiles were found to be similar 
to  published  CGH  profiles  and/or  consistent  with  previously 
reported  genomic  alterations,  and  mutations  were  found  to  be 
identical to the reported mutations (data not shown).
Normal  human  urothelial  (NHU)  cells  were  established  as 
finite  cell  lines  from  surgical  specimens  of  human  urothelium 
obtained with the approval of the local research ethics committee 
and full written consent from patients with no history of bladder 
cancer undergoing open urological procedures. A representative 
piece of each specimen was examined to confirm that it was histo-
logically normal and the remaining tissue was used to establish 
cultures, as detailed elsewhere (23,24). Briefly, the urothelium was 
detached from the stroma by incubation in Ca
+2- and Mg
+2-free 
Hanks balanced salt solution containing 10 mM HEPES pH 7.6, 
2 × 10
4 IU/mL aprotinin and 0.1% (w/v) EDTA. The urothelium 
was  collected,  disaggregated  in  200  U/mL  collagenase  type  IV 
(Sigma-Aldrich,  St.  Quentin  Fallavier,  France)  and  used  to  seed 
Primaria tissue culture flasks (Becton Dickinson, Le Pont de Claix, 
France). NHU cell cultures were routinely maintained in complete 
keratinocyte  serum-free  medium  (KSFMc),  consisting  of  KSFM 
supplemented with bovine pituitary extract and  endothelial growth 
factor,  at  the  concentrations  recommended  by  the  manufacturer 
(Invitrogen), together with 30 ng/mL cholera toxin (Sigma-Aldrich). 
NHU cell cultures were subcultured each time that they started to 
become confluent by incubation in phosphate-buffered saline sup-
plemented with 0.1% (w/v) EDTA for 5 minutes at 37°C, followed 
by treatment with trypsin–versene (containing 0.25% [w/v] trypsin 
and 0.02% [w/v] EDTA in phosphate-buffered saline) to detach the 
cells, which were harvested in KSFMc supplemented with 50 mg/mL 
soybean  trypsin  inhibitor  (Sigma-Aldrich)  (23).  In  these  experi-
ments, two independent NHU cell lines were used at passage 4.
RNA and DNA Extraction from Cell Lines
RNA and DNA were extracted from cell lines with Qiagen extrac-
tion kits (Qiagen, Courtaboeuf, France): the RNeasy Mini Kit for 
RNA extraction and the QIAamp DNA Mini Kit for DNA extrac-
tion. For RNA to be considered suitable for DNA array analysis, it 
had to fulfill two of the following three criteria: 1) RIN (RNA in-
tegrity number) above 7; 2) 28S to 18S ratio greater than 1.5; and 
3) intact profile with a flat baseline. RNA samples with 260/280 
nm absorbance ratios greater than 1.8 were considered suitable for 
RT-qPCR analysis. DNA was considered suitable for methylation 
or CGH analyses if it gave a visible band on an agarose gel with a 
smear above 2 kb when 300 ng was loaded, and if the 260/280 nm 
absorbance ratio was greater than 1.8.
Analysis of the Effect of Epigenetic Drugs on Gene 
Expression
For  analyses  of  the  effect  of  the  histone  deacetylase  inhibitor 
trichostatin A (TSA) (Calbiochem, Fontenay-sous-Bois, France) 
and/or  the  DNA  demethylating  agent  5-aza-deoxycytidine 
(Calbiochem) on transcript levels, normal and tumor cells were 
seeded  in  25  cm
2  dishes  at  a  density  of  8  ×  10
5  cells  per  dish. 
Cultures were treated the next day with 300 nM TSA for 16 hours, 
5 µM 5-aza-deoxycytidine for 72 hours, or 5 µM 5-aza-deoxycytidine 
for 48 hours followed by 300 nM TSA for 10 hours. These exper-
iments  were  repeated  twice  and  each  time,  each  condition  was 
tested in duplicate. The efficiency of the TSA treatment was con-
trolled by measuring the expression of the SMPD3 gene. We have 
found  this  gene  to  be  repressed  in  normal  bladder  and  cancer   
cell lines by histone methylation and hypoacetylation but not by 
Table 1. Patient and tumor characteristics
First set of  
tumors*
Second set of   
tumors
Patients N = 53 N = 40
  Sex  
    Males, No. (%) 43 (81) 32 (80)
    Females, No. (%) 10 (19) 8 (20)
  Mean age at surgery, yr ± SD 62.7 ± 11.0 66.9 ± 12.5
  Mean follow-up, mean ± SD 73 ± 44.6 44 ± 38.5
Bladder tumors  
  Clinical presentation (N = 57) (N = 40)
    Incident tumors, No (%) 44 (77) 33 (82.5)
    Recurrent tumors, No (%) 13 (23) 7 (17.5)
  Stage†  
    Ta 16 10
    T1 8 6
    T2 7 6
    T3 13 7
    T4 13 11
  Grade†  
    G1 6 2
    G2 16 9
    G3 35 29
  FGFR3 mutated tumors, No (%) 23 (40.5) 13 (32.5)
*  For the three patients from whom we studied several tumors, only the 
first surgical intervention was taken into account for the age at surgery and 
follow-up calculations.
†  Tumors were staged according to the TNM classification (16) and graded 
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DNA methylation (data not shown). The efficiency of the 5-aza-
deoxycytidine  treatment  was  controlled  by  monitoring  the  re-
expression of several methylated genes: CDH1 in T24, TCCSUP, 
and HT1376 cells; TMEFF2 in MGHU3, RT112, and JMSU1 
cells; and ANKRD30A (25) in NHU cells.
Quantitative Reverse Transcription–Polymerase Chain 
Reaction (RT-qPCR)
One microgram of total RNA was used for reverse transcription with 
20 pmol of random hexamers and 200 units of Moloney Murine 
Leukemia Virus (MMLV) reverse transcriptase. To assess mRNA 
levels by real-time quantitative PCR (RT-qPCR), we used either in-
dividual assays or the TaqMan low-density array on an ABI PRISM 
7900  real-time  thermal  cycler  (Applied  Biosystems,  Courtaboeuf, 
France). With both methods, all samples were run in duplicate. For 
all experiments that involved RNA from T1207 and CL1207 cells, 
both methods were used. For individual assays, we used the SYBR 
Green kit (Applied Biosystems) to measure the expression of the 
RNAs of interest (for primer sequences, see Supplementary Table 1, 
available online) and the TaqMan kit (assays-on-demand; Applied 
Biosystems) for the reference RNAs (18S rRNA). For TaqMan low-
density array, the same reference 18S rRNA was used; predesigned 
TaqMan probe and primer sets for the different genes were chosen 
from the Applied Biosystems catalog. The amounts of mRNAs of 
the genes of interest were normalized to that of the reference gene 
according to the 2
2DCt method (26).
DNA Methylation Analysis
We investigated the methylation status of the promoters by bisul-
fite sequencing or combined bisulfite restriction analysis (COBRA) 
assay (27). We used the Epitect kit (Qiagen) for bisulfite treatment 
of 2 µg of genomic DNA and its subsequent purification. This 
modified DNA was amplified as follows: initial incubation at 94°C 
for 4 minutes, followed by 35 cycles of denaturation at 94°C for 30 
seconds, annealing at Tm for 30 seconds and extension at 72°C for 
30 seconds, with Biolabs Taq Polymerase (Ozyme, Saint-Quentin-
en-Yvelines, France). For bisulfite sequencing, we cloned the pu-
rified PCR product using the TA cloning kit (Invitrogen, Cergy 
Pontoise, France) and sequenced 10 clones for each sample and 
gene. For the COBRA assay, the PCR products were digested for 
16 hours with a restriction enzyme recognizing a restriction site 
containing a CpG dinucleotide. When the corresponding CpG 
site is methylated, the PCR product is digested.
Chromatin Immunoprecipitation
Chromatin immunoprecipitation (ChIP) assays were carried out in 
duplicate in three 150 cm
2 dishes for untreated CL1207, TCCSUP, 
RT112, and NHU cells and for CL1207 cells treated with 300 nM 
TSA for 16 hours. Using an Active Motif kit (Active Motif, Rixensart, 
Belgium), chromatin was extracted from cell nuclei and sheared en-
zymatically.  An  extract  of  the  original  chromatin  was  kept  as  an 
internal standard (input DNA). The complexes were immunopre-
cipitated with 4 µg of rabbit polyclonal antibodies against trimethyl 
histone H3 lysine 27 (Upstate Biotechnology, Santa Cruz, CA), tri-
methyl histone H3 lysine 9 (Abcam, Cambridge, UK) or acetyl his-
tone H3 lysine 9 (Abcam) and Protein A/G PLUS-Agarose beads 
(Santa Cruz, Heidelberg, Germany) in dilution buffer containing 1% 
Triton X-100, 150 mM NaCl, 2 mM EDTA, 20 mM Tris–HCl at 
pH 8.0, and protease inhibitors. The amount of immunoprecipitated 
target was determined by real-time PCR, in duplicate, using the ABI 
PRISM  7900HT  Sequence  Detection  System  and  appropriate 
primer  sequences  (Supplementary  Table  1,  available  online).  For 
each sample and each promoter, an average Ct value was obtained for 
immunoprecipitated  material  and  for  the  input  chromatin.   
The  amount  of  immunoprecipitated  material  was  defined  as   
2
Ct(input DNA) - Ct(immunoprecipitated DNA).
Defining the MRES Phenotype
Two methods were used to define the MRES phenotype. The first 
method  used  individual  clustering  (Figure  1):  expression  of  a 
region was considered to be decreased in a given sample if, in the 
individual clustering for this region, the sample belonged to the 
cluster  arm  of  tumors  with  decreased  expression.  The  second 
method used the regional expression score: for each sample and 
each region, expression levels of all the genes in the region were 
log2-transformed and normalized; the regional expression score of 
a sample was calculated as the average of the differences between 
the expression in this sample and the average expression in normal 
samples of the genes in the region. Tumors were clustered accord-
ing to these regional expression scores.
FGFR3 Mutation Analysis
FGFR3 mutations were studied with the SNaPshot technique (28). 
Briefly, three regions that encompassed all of the FGFR3 muta-
tions reported in bladder cancer were amplified simultaneously. 
After the removal of excess primers and dNTPs, SnaPshot primers 
to  detect  the  following  FGFR3  mutations  (R248C,  S249C, 
G372C, Y375C, A393E, K652E, K652Q, K652M, K652T) were 
annealed to the PCR products and extended with a labeled dide-
oxynucleotide (see [28] for the primer sequences). The extended 
primers were analyzed on an automatic sequencer (ABI Prism 3100 
genetic analyzer; Applied Biosystems).
Statistical Analysis
Statistical  analysis  and  numerical  calculations  were  carried  out   
with R 2.6 (R Foundation for Statistical Computing, http://www. 
r-project.org/) and Amadea (Isoft, Gif-sur-Yvette, France). Fisher 
exact test was used to test the relationship between the MRES 
phenotype  and  various  histopathologic  and  molecular  traits  of 
bladder cancer. We calculated 95% confidence intervals for qRT-
PCR expression data for normal samples. All statistical tests were 
two-sided and P values less than .05 were considered to be statisti-
cally significant.
Results
Identification of  Chromosomal  Regions With  Decreased 
Expression in Bladder Tumors
We  previously  developed  a  large  scale  bioinformatics  approach 
that combined paired transcriptome and  CGH array data for the 
identification of regions of neighboring genes with correlated ex-
pression that was not dependent upon changes in copy number. 
The application of this method to a series of 57 bladder tumors led 
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with one to four regions per chromosome. These regions were 
candidates  for  control  by  regional  epigenetic  mechanisms  (11). 
Because we were principally interested in epigenetically silenced 
regions, we first searched for those regions that harbored genes 
with decreased expression with respect to normal urothelial sam-
ples.  For  each  gene  in  the  28  regions,  we  calculated  the  ratio 
between its level of expression in each tumor sample and its mean 
expression in five samples of mRNA from normal urothelium, as 
measured on Affymetrix arrays. We then used these expression 
ratios to cluster, for each region, all normal and tumor samples. 
This cluster analysis identified several types of regions. For eight 
regions (regions 1-1, 3-2, 3-5, 6-7, 7-2, 14-1, 19-3A, and 19-3B), 
we observed coordinately decreased gene expression in a subset of 
tumors (Figure 1). For six other regions (regions 2-3, 5-3, 5-4, 6-3, 
6-5, and 12-4), we observed coordinately increased gene expres-
sion in a subset of tumors (Figure 1 and data not shown). For two 
regions (2-7 and 17-7), one subset of tumors presented decreased 
gene expression and a different subset showed increased gene ex-
pression (Figure 1). The remaining regions displayed no clear ex-
pression pattern. Because we were interested in regions that were 
candidates  for  epigenetic  silencing,  we  focused  our  subsequent 
analysis  on  the  10  regions  that  had  decreased  gene  expression   
Figure 1. Clustering analyses to identify coordi-
nated gene expression patterns independent of 
copy  number  changes  in  bladder  tumors.  For 
each of the 28 chromosomal regions that con-
tained  genes  with  correlated  expression  inde-
pendent of copy number changes (11), tumors 
were subjected to hierarchical clustering based 
on gene expression levels. Each row represents 
such a gene, ordered according to its chromo-
somal position in the region, and each column 
represents  a  tumor  or  normal  tissue  sample. 
Only  genes  for  which  normal  samples  had  a 
“present”  signal  according  to  the  Affymetrix 
MAS5 algorithm were included. As shown in the 
color bar at the bottom of the figure, green indi-
cates  decreased  expression,  red  indicates 
increased  expression,  and  black  indicates  no 
change of gene expression, with respect to av-
erage expression in normal urothelium (n = 5). 
For each region, the subset of tumors with coor-
dinately  decreased  gene  expression  in  the 
region  is  boxed  in  green  and  the  subset  of 
tumors  with  coordinately  increased  gene  ex-
pression is boxed in red. N indicates the position 
of  the  normal  samples  and  the  green  arrows 
indicate the position of the T1207 bladder tumor 
from  which  the  CL1207  cell  line  was  derived. 
Different tumor expression patterns were identi-
fied among the 28 chromosomal regions con-
taining genes with coordinated expression. Ten 
regions (shown here) (1-1, 2-7, 3-2, 3-5, 6-7, 7-2, 
14-1, 17-7, 19-3A, and 19-3B) contained a subset 
of  tumor  samples  with  coordinated  decreased 
expression. These regions were potentially af-
fected by a regional epigenetic silencing mecha-
nism. Two of the 10 regions (2-7 and 17-7) also 
contained a subset of tumors with coordinated 
increased expression. Although region 19-3 was 
initially identified as a single region (11), it was 
separated here into two regions (regions 19-3A 
and 19-3B) because we found that it comprised 
two  well-spaced  clusters  of  genes  with 
decreased  expression  that  were  separated  by 
several  genes  whose  expression  was  not 
decreased in tumors compared to normal uro-
thelium  (data  not  shown).  Among  the  19 
remaining  regions,  six  presented  a  subset  of 
tumors with coordinated increased expression 
(one of these six region, region 12-4 is shown) 
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(1-1, 2-7, 3-2, 3-5, 6-7, 7-2, 14-1, 17-7, 19-3A, and 19-3B) in a 
subset of tumors (Figure 1).
To  determine  whether  coordinated  decreased  expression  af-
fected contiguous genes in these 10 regions, we extensively studied 
the expression of all genes within these regions by RT-qPCR, in-
cluding  both  the  genes  that  were  present  and  absent  on  the 
Affymetrix array (Figure 2, A and Supplementary Figure 1, avail-
able  online).  For  this  analysis,  we  used  mRNA  from  a  T4G2 
bladder  tumor,  T1207,  and  from  a  cell  line  derived  from  this 
tumor,  CL1207.  We  chose  to  study  tumor  T1207  because  it 
showed decreased gene expression in all 10 regions on Affymetrix 
arrays (Figure 1), it did not show any genetic loss in these regions, 
and a cell line derived from this tumor, CL1207 was available, 
allowing subsequent functional analyses. We found stretches of 
contiguous genes with coordinately decreased or  nonexpression 
within all of the regions except region 1-1. Both tumor T1207 and 
the cell line that was derived from it displayed identical stretches 
of genes with reduced expression (Figure 2, A and Supplementary 
Figure  1,  available  online).  A  schematic  representation  of  the 
stretches found in nine of the 10 regions is given in Figure 2, B.
Identification of Seven Regions Affected by Regional 
Epigenetic Silencing
To address whether the genes within the nine gene stretches that 
were underexpressed in tumor vs normal samples were silenced by 
an epigenetic mechanism, we first treated CL1207 cells with either 
the DNA demethylating agent, 5-aza-deoxycytidine, and/or with 
the histone deacetylase inhibitor TSA, then extracted mRNA from 
the cells and analyzed it by RT-qPCR. Compared with mRNA 
from untreated cancer cells, treatment with either drug was associ-
ated with the re-expression of most genes in seven of the regions 
(2-7, 3-2, 3-5, 7-2, 14-1, 19-3A, and 19-3B), suggesting that these 
regions were silenced by DNA methylation and/or histone modi-
fications  (Figure  3,  A  and  Supplementary  Figure  2,  available 
online). By contrast, when  NHU cells were treated with 5-aza-
deoxycytidine and TSA, expression was not increased for most of 
the genes in these regions, with the exception of some isolated 
genes (Figure 3, A and data not shown). Treatment of CL1207 
cells with 5-aza-deoxycytidine and/or TSA led either to no re-
expression or to the re-expression of only one isolated gene in each 
of two regions (regions 6-7 and 17-7; Supplementary Figure 2, 
available online). These two regions were therefore excluded from 
subsequent analysis.
We  then  investigated  the  involvement  of  DNA  methylation 
and histone hypoacetylation or methylation in the silencing of the 
seven  regions  that  were  re-expressed  after  5-aza-deoxycytidine 
and/or TSA treatment. We assessed DNA methylation by DNA 
sequencing and COBRA (digestion with an enzyme targeting an 
original CpG site). All of the CpG islands in regions 3-2 and 19-3A 
were studied, whether or not they overlapped gene promoters (for 
their locations, see Figure 2, B). For the other regions, we studied 
the  methylation  status  of  all  gene  promoter–associated  CpG 
islands for the genes that were re-expressed after 5-aza-deoxycytidine 
treatment. These methylation studies were performed on DNA 
from different tumors, including T1207, that had shown decreased 
gene  expression  in  the  regions  of  interest,  and  on  DNA  from   
the CL1207 bladder cancer cell line and from normal NHU cells. 
DNA methylation was rarely found in these regions and, when 
present, it was not necessary for silencing because some samples 
with  the  same  expression  profile  had  different  methylation 
status (Supplementary Figure 3, available online, and data not 
shown).
We assessed histone modifications by ChIP followed by quan-
titative PCR, using chromatin from CL1207 cells with and with-
out  TSA  treatment  and  from  NHU  cells.  We  analyzed  the 
promoter regions of all the genes located in regions 2-7, 3-2, and 
19-3A (Figure 3, B) and of one gene in each of the remaining 
regions (Figure 3, C). We studied two histone marks commonly 
associated with transcriptional inactivity (trimethylation of Lys9 of 
histone H3 [H3K9me3] and trimethylation of Lys27 of histone H3 
[H3K27me3]) and one histone mark commonly associated with 
transcriptional  activity  (acetylation  of  Lys9  of  histone  H3 
[H3K9ac]). The promoters of most genes in the silenced regions 
displayed high levels of methylation at the two repressive marks 
(H3K9me3 and H3K27me3) in chromatin from CL1207 bladder 
cancer  cells  compared  with  that  from  normal  (NHU)  cells. 
Conversely, the promoters of genes in the silenced regions lacked 
the histone mark associated with active genes (H3K9ac) in chro-
matin from CL1207 cells; however, it was present in chromatin 
from NHU cells (except in region 19-3A). When CL1207 cells 
were  treated  for  16  hours  with  TSA,  the  histone  methylation 
marks associated with gene inactivity decreased and the histone 
acetylation mark associated with gene activity increased in most 
gene promoters in the regions studied. These changes were ac-
companied by increased expression of these genes following TSA 
treatment.
Together, these results show that seven regions of chromatin 
with contiguous inactivated genes were silenced by a regional epi-
genetic mechanism involving aberrant histone modifications that 
led to the formation of facultative heterochromatin domains in 
cancer cells. DNA methylation was not involved in the silencing 
process. We termed this mechanism “RES” for regional epigenetic 
silencing.
MRES Phenotype in Bladder Tumors
To determine whether the epigenetic silencing of these seven chro-
mosomal regions (2-7, 3-2, 3-5, 7-2, 14-1, 19-3A, and 19-3B) oc-
curred randomly among tumors or in particular groups of tumors, 
we used two different strategies. In the first approach, we used the 
clustering  data  for  these  seven  regions  (Figure  1)  to  assess  how 
many  of  these  regions  were  silenced  in  each  of  the  57  bladder 
tumors. Twenty of 57 tumors (35%) did not present any silenced 
regions, 14 of 57 tumors (25%) had one or two silenced regions, 
whereas 23 of 57 tumors (40%) had three or more silenced regions, 
suggesting  a  concomitant  silencing  of  regions  in  a  subgroup  of 
tumors (Figure 4, A). In the second approach, we clustered tumors 
according to regional expression scores that were calculated by av-
eraging  the  difference  between  the  normalized  log2-expression 
values for genes in these regions in the tumor sample compared 
with those in normal tissue samples. Using this approach, 26 of 57 
tumors (46%) (including the 23 previously identified in Figure 4, A) 
clustered together and showed silencing of all or several of the seven 
regions (Figure 4, B). The simultaneous silencing of several chro-
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Figure 2. Further analysis of gene expression within the regions dis-
playing decreased expression. A) Analysis of all the genes contained 
in  regions  3-2  and  7-2  by  real-time  quantitative  polymerase  chain 
reaction (RT-qPCR). To confirm the Affymetrix data and to determine 
whether decreased expression affected stretches of contiguous genes, 
RT-qPCR  was  performed  on  RNA  from  the  T1207  human  bladder 
tumor, CL1207 (a cell line derived from T1207), and normal urothelial 
samples (n = 4). Expression was determined for all the genes in these 
regions,  including  the  genes  not  present  on  the  Affymetrix  array. 
Experiments were done in duplicate, in a TaqMan low-density array 
format, and expression levels were normalized relative to 18S ribo-
somal RNA. The histograms reflect the mean value of the duplicates. 
For normal samples, the error bars indicate the 95% confidence inter-
vals for four independent samples. For additional data for all other 
regions, see Supplementary Figure 1, available online. B) Summary of 
RT-qPCR data for the nine regions containing stretches of genes with 
decreased expression. Experiments were done with RNA from tumor 
T1207  and  its  derived  cell  line,  CL1207  (as  shown  in  [A]  and 
Supplementary Figure 1, available online). Stretches were defined by 
three or more consecutive genes with decreased expression in T1207 
and  CL1207  (ratio  to  average  expression  in  normal  samples  <0.5). 
Genes  that  were  not  expressed  were  included  in  these  stretches. 
Genes  are  ordered  according  to  their  chromosomal  locations;  their 
names, the orientation of transcription (shown with arrows), and the 
size of the regions are indicated. Genes with decreased expression are 
represented by a black rectangle, genes that were not expressed are 
indicated with a hatched rectangle and genes with no change in ex-
pression with respect to normal samples are indicated with a white 
rectangle. All of the CpG islands that overlap a gene promoter are 
shown below the genes (gray rectangles), and the numbers of CpG 
dinucleotides contained in the CpG islands are indicated. CpG islands 
that  do  not  overlap  promoters  are  shown  for  regions  2-7,  3-2,  and 
19-3A (hatched rectangles) because they were also used for methyla-
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Figure 3. Epigenetic silencing mechanisms in regions of decreased ex-
pression. A) Effect of 5-aza-deoxycytidine (5aza) and TSA treatments on 
gene  expression  in  CL1207  human  bladder  tumor  cells  vs  normal 
human urothelial (NHU) cells. Gene expression was measured by real-
time quantitative polymerase chain reaction (RT-qPCR) in RNA from 
CL1207 cells before (NT) and after treatment with the DNA demethylat-
ing agent 5aza, the histone deacetylase inhibitor TSA, or both and in 
RNA from NHU cells before (NT) and after treatment with both 5aza and 
TSA. Results are shown for two regions, region 2-7 (upper panels) and 
region 19-3A (lower panels) (for additional data for all other regions, 
see  Supplementary  Figure  2,  available  online).  For  each  treatment, 
RT-qPCR analyses were performed in two independent experiments, 
with each qPCR performed in duplicate. Results are expressed as the 
ratio between expression in treated cells and in untreated cells. The 
error bars indicate the variance between the means of the two indepen-
dent experiments. Treatments were scored as having an effect if there 
was a greater than 1.5-fold change between treated and untreated cells. 
B)  Histone  marks  in  regions  2-7,  19-3A,  and  3-2  in  chromatin  from 
CL1207 cells in the presence or absence of TSA treatment and from 
untreated NHU cells. Histone marks associated with the promoters of 
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in cancer that we have termed the “multiple regional epigenetic si-
lencing” (MRES) phenotype.
We examined the subgroup of 26 tumors with the MRES phe-
notype in terms of histopathologic and molecular characteristics. 
Strikingly,  25  of  these  26  samples  (96%)  were  from  muscle- 
invasive tumors (≥T2), and the remaining sample was from a high-
grade  (G3)  T1  tumor  (Figure  4,  B).  The  samples  that  did  not 
display the MRES phenotype (31 tumors and five normal urothe-
lial samples) included the eight remaining muscle-invasive tumors, 
eight  of  nine  high-grade  Ta  and  T1  tumors,  all  15  low-grade   
(G1 and G2) Ta and T1 tumors, and all five normal samples.
We further examined whether the MRES phenotype was more 
associated with either of the two pathways of bladder cancer pro-
gression (Figure 4, C). It is generally thought that most muscle-
invasive  bladder  tumors  (T2–T4)  develop  from  CIS  (29).  The 
second pathway of bladder cancer progression involves the devel-
opment of stage Ta tumors, usually of low grade, which rarely 
progress to muscle-invasive tumors (Figure 4, C) (32). This path-
way  is  associated  with  a  high  frequency  of  activating  fibroblast 
growth factor receptor 3 (FGFR3) gene mutations, whereas CIS-
associated tumors have few, if any, such mutations (30).
Dyrskjøt et al. (31) have reported a  CIS-associated signature 
from bladder cancer transcriptome data. We looked for a possible 
overlap in our data between the MRES phenotype and this signa-
ture  by  examining  expression  of  the  61  genes  present  on  our 
Affymetrix U95A array out of the 100 genes reported by Dyrskjøt 
et al. (31). Twenty-five of the 57 tumors presented the CIS signa-
ture,  and  remarkably,  all  25  displayed  the  MRES  phenotype 
(Figure 4, D). The association between the MRES phenotype and 
the CIS signature was highly statistically significant (P < 10
214, 
Fisher test). Only one tumor displayed the MRES phenotype but 
not the CIS signature.
We  also  looked  for  the  presence  of  FGFR3  mutation  as  a 
marker  for  the  alternative  tumor  progression  pathway,  the  Ta 
pathway (Figure 4, C). In our series of 57 tumors, 23 tumors had 
an FGFR3 mutation, and all but one of these tumors belonged to 
the  group  lacking  the  MRES  phenotype  (the  FGFR3  mutated 
tumor with the MRES phenotype also lacked the CIS signature). 
The absence of FGFR3 mutation is a characteristic trait of tumors 
with  the  MRES  phenotype  (P  <  10
26).  The  MRES  phenotype 
remained associated with the CIS signature and the presence of 
FGFR3 mutations remained associated with non-MRES tumors 
if we limited the analysis to muscle-invasive tumors (P < 10
26 and 
P = .008, respectively).
We  analyzed  specimens  from  three  patients  with  multiple 
tumors (two patients had two tumors and one patient had three 
tumors). All tumors from a given patient had the same MRES 
status and CIS signature (Figure 4, B). It should be noted that, 
when considering only one tumor per patient, we obtained iden-
tical results for the clustering analyses presented above and for the 
relationships between the MRES phenotype, the CIS signature 
and  the  absence  of  FGFR3  mutation  (Supplementary  Figure  4, 
available online, and data not shown).
The  existence  of  the  MRES  phenotype,  its  association  with 
muscle-invasive tumors with the CIS-associated signature and with 
a low rate of FGFR3 mutations, was also confirmed with an inde-
pendent set of tumors (n = 40). These data are available online 
(Supplementary Figure 5, available online).
The MRES Phenotype in Bladder Cancer Cell Lines
To determine whether the MRES phenotype was also found in 
bladder tumor cell lines, we used a panel of established bladder 
cancer–derived cell lines that were representative of the diversity 
of bladder tumors. We used two cell lines that were derived from 
well-differentiated tumors (MGHU3, which has mutated FGFR3; 
and RT112) and four cell lines that, like CL1207, were derived 
from high-grade tumors (T24, TCCSUP, HT1376, and JMSU1; 
none with mutated FGFR3). We also included NHU cells in the 
analysis. We investigated the effect of TSA on the re-expression of 
the  genes  within  the  seven  epigenetic  regions  that  defined  the 
MRES phenotype (Supplementary Figure 6, available online). We 
have provided a summary of the effects of treatment on the dif-
ferent cell lines (Figure 5, A). Two groups of cell lines were clearly 
distinguished. In the first group (NHU, MGHU3, RT112, and 
T24),  most  of  the  genes  were  not  re-expressed.  In  the  second 
group  of  cell  lines  (TCCSUP,  HT1376,  and  JMSU1),  as  in 
CL1207,  the  genes  in  most  of  the  silenced  regions  were  re-
expressed after TSA treatment, consistent with the existence of an 
MRES phenotype among these cell lines. Similar to what we had 
observed among tumors, the cell lines with the MRES phenotype 
were derived from high-stage and high-grade tumors, whereas all 
but one of the other cell lines were well differentiated (RT112) or 
derived from a low-grade and low-stage tumor with the FGFR3 
mutation (MGHU3). The one exception, the T24 cell line, has an 
HRAS mutation (33), and tumors with such mutations are thought 
to follow the Ta pathway (34,35). ChIP experiments to assess the 
H3K9me3, H3K27me3, and H3K9ac histone marks were previ-
ously  performed  on  chromatin  from  the  CL1207  cell  line  and 
silenced genes (H3K9me3 and H3K27me3) or expressed genes (H3K9Ac) 
were  investigated  by  chromatin  immunoprecipitation  (ChIP)  assays. 
ChIP assays were performed for all promoters in regions 2-7 (upper 
panels), 19-3A (middle panels) and 3-2 (lower panels), using antibodies 
against posttranslational modifications of histone H3: trimethyl lysine 9 
(H3K9me3; left panels), trimethyl lysine 27 (H3K27me3; middle panels) 
and acetyl lysine 9 (H3K9ac; right panels). The bar graph shows the 
amount of immunoprecipitated target DNA, expressed as a percentage 
of total input DNA, measured in duplicate by qPCR. Levels of H3K9me3 
and H3K27me3 in the promoter of the ubiquitously expressed GAPDH 
gene served as a negative control in chromatin from both cell types. 
The error bars indicate the variance between the means of two inde-
pendent experiments. C) Histone marks in regions 3-5, 7-2, 14-1, and 
19-3B  in  chromatin  from  TSA-treated  or  untreated  CL1207  cells  and 
from untreated NHU cells. In all other regions that presented a stretch 
of coordinately silenced genes that were re-expressed after TSA or 5aza 
treatment, experiments were done as in (B) except that ChIP assays 
were performed for only one gene promoter per region (eg, the pro-
moter of BSN for region 3-5, HOXA1 for region 7-2, DHRS2 for region 
14-1, and JAK3 for region 19-3B).
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Figure 4. Presence of a multiple regional epigenetic silencing (MRES) 
phenotype in bladder cancer and its relationship to the two pathways 
of bladder tumor progression. A) Determination of the number of epi-
genetically silenced regions for each tumor in the set of 57 bladder 
tumors. This panel was deduced from the cluster analysis data in Figure 
1 for each of the seven epigenetically controlled regions (regions 2-7, 
3-3, 3-5, 7-2, 14-1, 19-3A, and 19-3B). Each row represents a chromo-
somal region, and each column a tumor or normal sample. For each 
tumor, decreased expression of a given chromosomal region (ie, place-
ment within the green box in Figure 1) is denoted by a green rectangle, 
whereas equal or increased expression is denoted by a white rectangle. 
Twenty-three tumors (those below the horizontal green line) displayed 
decreased expression of at least three regions. The position of tumor 
T1207 is indicated by a green arrow. B) Cluster analysis of 57 tumor 
samples and five normal samples according to the level of gene expres-
sion in the seven epigenetically silenced regions. Samples are clustered 
according to their regional expression scores, which correspond to the 
average  levels  of  gene  expression  in  each  region  (see  “Methods”). 
Tumors that displayed decreased expression in several regions (below 
the horizontal green line) define a  MRES phenotype. All samples are 
annotated with their stage and grade, presence or absence of a carci-
noma in situ (CIS)-associated gene expression signature (Figure 4, D) 
and their FGFR3 mutation status. Tumors that had at least three chro-
mosomal regions with decreased gene expression in Figure 4, A are 
also indicated. The tumors from the three patients with multiple tumors 
are indicated by three different symbols. The patient indicated by a 
circle had two synchronous T3-G3 tumors. The patient indicated by a 
square had one T2-G2 primary tumor and then a T1-G2 tumor. The 
patient indicated by a diamond had three synchronous T4-G3 tumors. 
The cluster analysis was not affected by the exclusion of regional ex-
pression scores for tumors displaying genetic loss in the corresponding 
region (data not shown). C) Schematic representation of the two pathways 
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NHU cells for three regions in detail (2-7, 3-2, and 19-3A) and for 
one gene in each of the other regions (3-5, 7-2, 14-1, and 19-3B) 
(Figure 3, B and C). We studied the same marks in chromatin from 
two additional cell lines, one with (TCCSUP) and the other with-
out  (RT112)  the  MRES  phenotype  (Supplementary  Figure  7, 
available online). For all seven regions, we observed higher levels 
of  trimethylation  at  lysines  9  and  27  in  histone  3  from  the 
TCCSUP cells compared with histone 3 from the RT112 cells. 
Levels of histone 3 acetylation at lysine 9 were higher in RT112 
cells for some genes. Therefore, trimethylation of lysines 9 and 27 
clearly differentiated cancer cell lines with the MRES phenotype, 
such as TCCSUP and CL1207 cells, from normal (NHU) cells 
and from other cancer cell lines, such as RT112. A summary of the 
histone marks in the epigenetically silenced regions for all three 
cell lines (RT112, CL1207, and TCCSUP) compared with NHU 
cells is presented (Figure 5, B).
of bladder cancer progression. In bladder cancer, two different path-
ways can lead to invasive tumors: the superficial Ta tumor pathway, 
which rarely leads to progression, and the  CIS pathway, in which the 
superficial  lesions  (CIS)  are  high  grade  and  very  often  progress  to 
lamina propria–invasive T1 and then to muscle-invasive T2-T4 tumors 
(29). The percentages of FGFR3 mutations at the different stages of 
tumor progression in the two pathways are taken from reference (30). 
D) Separation of the 57 bladder tumors according to the CIS-associated 
gene expression signature previously defined by Dyrskjøt et al. (31). 
Sixty-one of the 100 genes reported by Dyrskjøt et al. were represented 
on  the  Affymetrix  array  used  (U95A).  Of  these  61  genes,  26  corre-
sponded  to  genes  with  increased  expression  and  35  to  genes  with 
decreased expression in bladder cancers that had the CIS-associated 
signature compared with those that did not (31). The 62 samples (57 
tumor samples and five normal urothelial samples) clustered into two 
groups with respect to the CIS-associated gene expression signature.
Figure 4 (continued).
Figure 5. The multiple regional epigenetic silencing (MRES) phenotype 
in bladder cancer cell lines. A) Summary of the effect of TSA treatment 
on gene expression in the epigenetically silenced regions in bladder 
cancer and normal urothelial cells in culture. A gene was considered to 
be  re-expressed  if  its  expression  level  changed  1.5-fold  or  more 
between treated and untreated cells (for original data, see Supplementary 
Figure 6, available online). A region was considered to be re-expressed 
if at least two neighboring genes were re-expressed after treatment: a 
yellow box indicates that a group of at least two neighboring genes 
were re-expressed, whereas a red box indicates that all genes were re-
expressed. A cell line was considered to present the MRES phenotype 
if  most  of  the  regions  were  re-expressed  following  TSA  treatment.   
B)  Summary  of  the  changes  in  histone  marks  in  the  epigenetically 
silenced regions in MRES and non-MRES tumor cell lines. This panel 
summarizes the changes in histone marks associated with the promoter 
of inactive (H3K9me3 and H3K27me3) and active (H3K9Ac) genes for 
the different regions in two cell lines presenting the MRES phenotype 
(TCCSUP and CL1207) and one cell line without the MRES phenotype 
(RT112) compared with NHU cells. The histone marks were assessed by 
chromatin  immunoprecipitation,  with  specific  antibodies  directed 
against the different marks (for original data, see Figure 3, B and C and 
Supplementary Figure 7, available online). All gene promoters were 
studied within regions 2-7, 3-2, and 19-3A and one gene promoter per 
region was studied for all the other regions (the promoter of BSN for 
region 3-5, HOXA1 for region 7-2, DHRS2 for region 14-1 and JAK3 for 
region 19-3B). For each cell line, the histone marks of the promoters of 
the genes within the different regions were compared with the histone 
marks found at the same promoter in NHU cells. Within each region 
and for each cell line and histone mark, we have indicated the per-
centage of promoters with a histone mark that is modified compared 
with the corresponding site in NHU cells. The inactive marks (H3K9me3 
and H3K27me3) were scored as being modified if we observed a two-
fold increase in modification at the same position in the promoter in the 
tumor  cell  line,  as  compared  with  NHU  cells.  For  the  active  mark 
(H3K9ac), we scored the mark as modified if the mark displayed a more 
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Discussion
We have shown that whole chromosomal regions can be coordi-
nately silenced by an epigenetic mechanism in a subset of bladder 
tumors, hence defining a  MRES phenotype in cancer. The sub-
group of tumors with the MRES phenotype is associated with a 
CIS gene expression signature, with higher tumor grade and stage, 
including  most  muscle-invasive  tumors,  and  usually  with  the 
absence of FGFR3 mutations. The silencing occurred in associa-
tion with histone H3K9 and K27 hypermethylation and H3K9 
hypoacetylation of promoter regions, mimicking the formation of 
facultative heterochromatin domains.
Several  regions  of  epigenetic  silencing  have  previously  been 
identified in cancer. Three of them overlap with regions that we 
identified in bladder cancer: at 3p22.3, a 1.1 Mb region in colon 
cancer (36), which included our 144 kb region 3-2; at 7p15.2, a 
region of about 100 kb of the HOXA cluster in breast cancer (12) 
and a region of 1.09 Mb which included the HOXA cluster in 
prostate cancer (14), which both overlapped with our region 7-2; 
and at 2q31.1, a region of 109 kb of the HOXD cluster in breast 
cancer (37), which overlapped with our region 2-7. The repeated 
identification  of  these  sites  suggests  that  some  chromosomal 
regions may be prone to RES in different cancers. However, there 
is some cancer tissue–type specificity because the region previously 
identified at 2q14.2 in colorectal cancer (13) was not silenced in 
bladder cancer, and the 3-5, 14-1, 19-3A, and 19-3B regions iden-
tified here in bladder cancer were not silenced in breast or cervical 
cancers (data not shown).
In one of the silenced regions, region 14-1, one gene (NGDN) 
was not silenced in any of the tumors that showed silencing of this 
region. The reason that NGDN has “escaped” the global pattern of 
the chromosomal region that surrounds it is unclear, although a 
similar  phenomenon  has  been  reported  for  the  inactive  X 
chromosome in women, in which most genes are silenced, but a 
few can escape inactivation (38).
The different types of histone marks that we identified in the 
epigenetically silenced regions, especially trimethylation of lysines 
27 and 9, are characteristic of silent and heterochromatic regions 
of the genome in normal tissue (39). Thus, it would appear that the 
chromatin structure of the altered chromosomal regions that we 
have identified has shifted from a euchromatic transcriptionally 
competent state in NHU cells (where such marks are not found or 
are found only at low levels) to a facultative heterochromatic con-
formation that inhibits transcription (40). There are several pos-
sible explanations for this change in chromatin structure. Among 
them, a condensation of chromatin and/or a modification of the 
localization of these regions within the nucleus (41,42) may affect 
their transcription status. Indeed, the HOXD cluster is regulated 
by such mechanisms during development (43,44) and is dysregu-
lated in tumors with the MRES phenotype. Consequently, RES in 
cancer may correspond to a deregulation of the normal process of 
chromatin domain regulation that occurs during development. To 
confirm this hypothesis, it would be worth studying the status of 
the six other silenced regions during normal development to deter-
mine  whether  those  genes  are  co-regulated,  like  the  HOXD 
cluster.
Another  epigenetic  phenotype  involving  DNA  hypermethyl-
ation, the CpG island methylator phenotype (CIMP), has been 
described in colon cancer (45). In this case, multiple isolated loci, 
rather than chromosomal regions, simultaneously undergo DNA 
methylation. This phenotype is associated with a subtype of colon 
tumors that harbor specific molecular and clinical characteristics 
such as microsatellite instability, a high frequency of BRAF V600E 
mutation, low frequencies of p53 mutations, proximal tumor loca-
tion,  poor  differentiation,  mucinous  histology,  infiltrating  lym-
phocytes, female sex, higher age at diagnosis, and microsatellite 
instability (46,47).
Clinical and molecular evidence indicates that bladder cancer 
develops through two pathways, the Ta pathway and the CIS path-
way (Figure 4, C) (29,30,48). Ta tumors, which are mostly of low 
grade, rarely progress to muscle-invasive disease (32). Isolated CIS 
is  rarely  observed;  it  is  encountered  predominantly  with  other 
urothelial tumors (49). The presence of concomitant CIS lesions 
with papillary tumors in the bladder is associated with a high risk 
of disease progression to a muscle-invasive stage (32), and CIS is 
considered to be the main precursor of muscle-invasive tumors 
(29). One of the strongest molecular arguments in favor of the 
two-pathway  model  is  the  high  frequency  of  FGFR3-activating 
mutations (75%) in Ta low-grade tumors, their absence in  CIS 
and their low frequency (10%–16%) in muscle-invasive tumors 
(30,50). We show here that the MRES phenotype was associated 
to a striking degree with muscle-invasive tumors and almost com-
pletely overlapped with the CIS-associated signature identified by 
Dyrskjøt et al. (31). In addition, FGFR3 mutations were found 
mostly in tumors without the MRES phenotype. Our data thus 
provide  further  support  for  the  existence  of  two  pathways  of 
bladder tumor progression: the Ta pathway, characterized by a low 
propensity to progress and by a high rate of FGFR3 mutation, and 
the CIS pathway, characterized by an epigenetic phenotype that 
includes  the  concomitant  silencing  of  several  chromosomal 
regions. Further characterization of bladder cancer progression is 
required to determine whether the MRES is already present in 
CIS lesions or appears at a later stage. In support of the association 
between the MRES phenotype and the CIS pathway, cell lines 
with (or without) the MRES phenotype have the same characteris-
tics as tumors with (or without) the MRES phenotype. Indeed, cell 
lines with the MRES phenotype were derived from high-stage and 
high-grade tumors, whereas all but one (T24) of the other cell 
lines were well differentiated (RT112) or derived from a low-grade 
and  low-stage  tumor  with  an  activating  FGFR3  mutation 
(MGHU3). However, the T24 cell line fits our model because this 
cell line has an HRAS mutation, and tumors with such mutations 
are thought to follow the Ta pathway (34,35).
In our series of bladder cancer patients, most of the muscle-
invasive tumors displayed the MRES phenotype, whereas most of 
the Ta and T1G2 tumors did not present this phenotype, consis-
tent with the two-pathway model of tumor progression. Most of 
the T1G3 tumors (eight of 11) were MRES negative. Several ex-
planations may account for this observation: in our series, most of 
the T1G3 tumors may have arisen via the Ta pathway, and were 
therefore MRES negative; the MRES phenotype may appear prin-
cipally  at  the  transition  between  the  T1  and  T2  stages  during 
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a third pathway of tumor progression, not derived from Ta or 
CIS. The detection of FGFR3 mutations, which are preferentially 
associated with the Ta pathway, in five of the eight T1G3 tumors 
without  the  MRES  phenotype  is  consistent  with  the  first 
hypothesis.
Our  study  had  some  limitations.  Because  no  isolated  carci-
nomas in situ were included in our study, we do not yet know if 
the MRES phenotype is already present at the CIS stage or if it 
appears within the CIS pathway, but at later stages. We were able 
to study histone marks and perform functional studies in vitro 
because we had a cell line derived from one tumor of our series. 
However, it will be important in the future to study the histone 
marks associated with the epigenetically silenced regions in vivo, 
that is, directly in tumor samples of known MRES status. In our 
prognostic studies, the number of bladder cancer patients in our 
series was relatively small, but we nonetheless found that muscle-
invasive  tumors  with  the  MRES  phenotype  tended  to  have  a 
worse outcome than muscle-invasive tumors without the MRES 
phenotype (P = .08). This observation requires confirmation in a 
larger series of tumors: too few progression events were available 
for non-muscle-invasive tumors for any firm conclusions to be 
drawn.
The identification of the MRES phenotype has potential clin-
ical implications for the prognosis of noninvasive or muscle-inva-
sive  tumors  and  for  treatment.  The  silenced  regions  that 
characterize the MRES phenotype contain known (PLCD1 [51], 
DLEC1  [52])  or  potential  (HOXA5  [53,  54])  tumor  suppressor 
genes. We anticipate that the silencing of multiple regions pro-
duces a concomitant inactivation of tumor suppressor genes that 
may act in concert to drive neoplastic progression of the CIS path-
way. Because epigenetic aberrations are reversible, our work sug-
gests that treatments that target H3K9 and H3K27 methylation 
and/or  H3K9  hypoacetylation  represent  a  new  avenue  for  the 
therapy of a particularly aggressive group of cancers.
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